PI
PGNX

PineBridge Investments’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

PineBridge Investments’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,396
Closed -$53K – 1217
2019
Q3 		$53K Buy
10,396
+3,965
+62% +$19.8K ﹤0.01% 1032
2019
Q2 		$40K Buy
+6,431
New +$31K ﹤0.01% 951
2017
Q4 		– Sell
-8,721
Closed -$64K – 1179
2017
Q3 		$64K Sell
8,721
-531
-6% -$3.37K ﹤0.01% 1018
2017
Q2 		$63K Buy
9,252
+115
+1% +$849 ﹤0.01% 995
2017
Q1 		$86K Buy
+9,137
New +$91.2K ﹤0.01% 958

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PineBridge Investments's PGNX Position: Q4 2019 in Review

PineBridge Investments sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 10,396 shares — an estimated $53K sold.

PineBridge Investments first reported a position in PGNX in Q1 2017 and held it in 5 quarters. The position peaked at $86K in Q1 2017. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • PineBridge Investments reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • PineBridge Investments sold 10,396 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $53K.
  • PineBridge Investments first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 5 quarters.
  • PineBridge Investments's Progenics Pharmaceuticals Inc position peaked at $86K in Q1 2017.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on PineBridge Investments's 13F filing for Q4 2019, filed 13 Feb 2020.